Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease

Pediatr Infect Dis J. 2009 Aug;28(8):753-4. doi: 10.1097/INF.0b013e31819c6f3a.

Abstract

Visceral leishmaniasis is a severe form of infection caused by a parasite endemic along the Mediterranean coast. Complications such as infection-associated hemophagocytic syndrome can occur despite correct therapy. We report visceral leishmaniasis-associated infection-associated hemophagocytic syndrome in 3 patients with chronic granulomatous disease.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Amphotericin B / therapeutic use
  • Animals
  • Antiprotozoal Agents / therapeutic use
  • Child
  • Fatal Outcome
  • Female
  • Granulomatous Disease, Chronic / complications*
  • Humans
  • Interferon-gamma / therapeutic use
  • Leishmaniasis, Visceral / complications*
  • Leishmaniasis, Visceral / diagnosis
  • Leishmaniasis, Visceral / drug therapy
  • Lymphohistiocytosis, Hemophagocytic / complications*
  • Lymphohistiocytosis, Hemophagocytic / diagnosis
  • Lymphohistiocytosis, Hemophagocytic / etiology
  • Male
  • Recombinant Proteins

Substances

  • Antiprotozoal Agents
  • Recombinant Proteins
  • liposomal amphotericin B
  • Amphotericin B
  • Interferon-gamma